Cambridge, Mass., based Sirtris Pharmaceuticals raised at least $60 million in an initial offering, after pricing six million shares in the middle of its anticipated range of $9 to $11 apiece. The company is developing drugs that aim to mimic the health benefits of calorie-restricted diets, which have been shown to greatly extend life in a variety of animals. Sirtris’ drugs are designed to activate a protein called Sirt1, which some scientists believe may be responsible for the beneficial effects of caloric restriction.
The company’s initial drugs, which include a proprietary formulation of resveratrol — a substance found in red wine that seems to offset the effects of high-calorie diets in mice — are aimed at treating diseases related to aging, including type 2 diabetes.
[aditude-amp id="flyingcarpet" targeting='{"env":"staging","page_type":"article","post_id":13777,"post_type":"story","post_chan":"none","tags":null,"ai":false,"category":"none","all_categories":"business,","session":"B"}']VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Learn More